Head to Head Comparison: Azenta (NASDAQ:AZTA) vs. Champions Oncology (NASDAQ:CSBR)

Azenta (NASDAQ:AZTA – Get Free Report) and Champions Oncology (NASDAQ:CSBR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

This table compares Azenta and Champions Oncology”s revenue, earnings per share (EPS) and valuation.

Champions Oncology has lower revenue, but higher earnings than Azenta. Champions Oncology is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Azenta and Champions Oncology, as reported by MarketBeat.

Azenta presently has a consensus target price of $41.20, suggesting a potential upside of 15.89%. Given Azenta’s stronger consensus rating and higher probable upside, analysts plainly believe Azenta is more favorable than Champions Oncology.

Volatility and Risk

Azenta has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Institutional and Insider Ownership

99.1% of Azenta shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 10.9% of Azenta shares are owned by company insiders. Comparatively, 46.3% of Champions Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Azenta and Champions Oncology’s net margins, return on equity and return on assets.

Summary

Azenta beats Champions Oncology on 9 of the 13 factors compared between the two stocks.

About Azenta

(Get Free Report)

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

About Champions Oncology

(Get Free Report)

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.